Islatravir Once Monthly for PrEP Demonstrates Favorable Safety/Tolerability and Meets Pharmacokinetic Threshold Target in Blinded Interim Analysis of Phase IIa Trial

January 27-28 and February 3-4, 2021
Interim analysis showed that islatravir administered once monthly achieved the prespecified pharmacokinetic threshold for predicted HIV pre-exposure prophylaxis efficacy.
Format: Microsoft PowerPoint (.ppt)
File Size: 227 KB
Released: January 30, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Latesha Elopre and CCO: starting HIV pre-exposure prophylaxis (PrEP). DISCOVER study, CDC guidance, racial/ethnic disparities, overcoming barriers

Latesha Elopre, MD, MSPH Released: June 7, 2021

Slides from Latesha Elopre and CCO: starting HIV preexposure prophylaxis (PrEP). DISCOVER study, CDC guidance, racial/ethnic disparities, overcoming barriers.

Latesha Elopre, MD, MSPH Released: June 7, 2021

In this vlog from Clinical Care Options (CCO), Dr. Ethel Weld demonstrates HIV-ASSIST as a resource for selecting ART in a patient with comorbidities

Ethel D. Weld, MD, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.25 Medical Knowledge MOC point(s) Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Physician Assistants: maximum of 0.25 hours of AAPA Category I CME credits Released: May 27, 2021 Expired: May 26, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue